Literature DB >> 17576697

Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections.

Michael D Parkins1, Deana M Sabuda, Sameer Elsayed, Kevin B Laupland.   

Abstract

OBJECTIVES: Although inadequate antimicrobial therapy has been demonstrated in multiple studies to increase the risk for death in bacterial infections, few data investigating the effect of antifungal therapy on outcome of serious fungal disease are available. We sought to assess the adequacy of empirical therapy and its effect on mortality in invasive Candida species infections.
METHODS: Population-based surveillance of all patients with Candida spp. cultured from blood and/or cerebrospinal fluid was conducted. Adequacy of empirical therapy was assessed according to published guidelines.
RESULTS: During a 5 year period, 207 patients had an invasive Candida spp. infection identified; in 199 cases (96%) adequate data were available for assessment of treatment and outcome at hospital discharge. One hundred and three (52%) cases were due to Candida albicans, 44 (22%) were due to Candida glabrata and the remainder were due to other species. Between the time of culture draw and reporting of a positive culture, only 64 (32%) patients were treated with empirical therapy; this was deemed adequate in 51 (26%). Patients who received adequate empirical therapy had a significant decrease in crude mortality [14/51 (27%) versus 68/148 (46%); risk ratio 0.60 (95% confidence interval 0.37-0.96); P = 0.02]. After adjusting for age and the need for intensive care unit admission in logistic regression analysis, the use of adequate empirical therapy was independently associated with a reduced risk for death [odds ratio 0.46 (95% confidence interval 0.22-1.00); P = 0.05].
CONCLUSIONS: Adequate empirical therapy is used in a minority of patients with invasive Candida spp. infections but is associated with improved survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576697     DOI: 10.1093/jac/dkm212

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  64 in total

Review 1.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

2.  Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United kingdom.

Authors:  Andrew M Borman; Adrien Szekely; Michael D Palmer; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2012-05-30       Impact factor: 5.948

3.  A Risk Score for Fluconazole Failure among Patients with Candidemia.

Authors:  Luis Ostrosky-Zeichner; Rachel Harrington; Nkechi Azie; Hongbo Yang; Nanxin Li; Jing Zhao; Valerie Koo; Eric Q Wu
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

4.  Validation of 24-hour flucytosine MIC determination by comparison with 48-hour determination by the Clinical and Laboratory Standards Institute M27-A3 broth microdilution reference method.

Authors:  Shawn R Lockhart; Carol B Bolden; Naureen Iqbal; Randall J Kuykendall
Journal:  J Clin Microbiol       Date:  2011-10-19       Impact factor: 5.948

Review 5.  Candida colonization and candiduria in critically ill patients in the intensive care unit.

Authors:  Pierluigi Viale
Journal:  Drugs       Date:  2009       Impact factor: 9.546

6.  Comparative study of the prevalence of sepsis in patients admitted to dermatology and internal medicine wards.

Authors:  Luiz Maurício Costa Almeida; Michelle dos Santos Diniz; Lorena dos Santos Diniz; Jackson Machado-Pinto; Francisco Chagas Lima Silva
Journal:  An Bras Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.896

7.  Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.

Authors:  M A Pfaller; L B Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2011-02-02       Impact factor: 5.948

8.  Selective digestive tract decontamination: A tough pill to swallow.

Authors:  Kevin B Laupland; David N Fisman
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

9.  In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study.

Authors:  He Wang; Meng Xiao; Sharon C-A Chen; Fanrong Kong; Zi-Yong Sun; Kang Liao; Juan Lu; Hai-Feng Shao; Yan Yan; Hong Fan; Zhi-Dong Hu; Yun-Zhuo Chu; Tie-Shi Hu; Yu-Xing Ni; Gui-Ling Zou; Ying-Chun Xu
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

Review 10.  [Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine].

Authors:  C Lichtenstern; S Swoboda; M Hirschburger; E Domann; T Hoppe-Tichy; M Winkler; C Lass-Flörl; M A Weigand
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.